An Open-label, Multi-center Everolimus Roll-over Protocol for Patients Who Have Completed a Previous Novartis-sponsored Everolimus Study and Are Judged by the Investigator to Benefit From Continued Everolimus Treatment
Phase of Trial: Phase IV
Latest Information Update: 22 May 2019
At a glance
- Drugs Everolimus (Primary) ; Octreotide
- Indications Cancer
- Focus Adverse reactions
- Sponsors Novartis
- 26 Feb 2017 Trial has been completed in Spain.
- 27 Nov 2016 Planned End Date changed from 1 Sep 2022 to 1 May 2023.
- 27 Nov 2016 Planned primary completion date changed from 1 Sep 2022 to 1 May 2023.